Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

(2017) Carol Wysham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

(2017) Wendy Lane et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Type 2 diabetes

(2017) Sudesna Chatterjee et al.   LANCET

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

(2017) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin

(2016) Albrecht Fiesselmann et al.   ACTA DIABETOLOGICA

Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus

(2016) J. N. Clements et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL

(2016) Jennifer N. Clements et al.   CLINICAL PHARMACOKINETICS

Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back

(2016) Ofri Mosenzon et al.   DIABETES CARE

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

(2016) M. Matsuhisa et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

(2016) Y. Terauchi et al.   DIABETES OBESITY & METABOLISM

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)

(2016) Munehide Matsuhisa et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

(2016) Matthew C. Riddle et al.   Diabetes Technology & Therapeutics

Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

(2016) Hannah A. Blair et al.   DRUGS

Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance

(2016) David R. Owens   Expert Opinion on Drug Metabolism & Toxicology

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

(2016)   LANCET

Concepts and clinical use of ultra-long basal insulin

(2016) Freddy Goldberg Eliaschewitz et al.   Diabetology & Metabolic Syndrome

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

(2015) Przemyslaw Rys et al.   ACTA DIABETOLOGICA

New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus

(2015) Jennifer Goldman et al.   ANNALS OF PHARMACOTHERAPY

Closed loop insulin delivery in diabetes

(2015) Tadej Battelino et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

(2015) Philip D. Home et al.   DIABETES CARE

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

(2015) R. Ritzel et al.   DIABETES OBESITY & METABOLISM

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

(2015) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi

(2015) H. Yki-Järvinen et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials

(2015) D. Russell-Jones et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain

(2015) Cristóbal Morales et al.   Diabetes Therapy

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain

(2015) Cristóbal Morales et al.   Diabetes Therapy

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

(2014) Matthew C. Riddle et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

New Insulin Glargine 300 units{middle dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 units{middle dot}mL-1

(2014) R. H. A. Becker et al.   DIABETES CARE

U300, a novel long-acting insulin formulation

(2014) Gemma Sutton et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus

(2014) Saygın Abalı et al.   PEDIATRIC DIABETES

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

(2014) A. C. Tricco et al.   BMJ-British Medical Journal

Will the next generation of basal insulins offer clinical advantages?

(2013) A. J. Garber   DIABETES OBESITY & METABOLISM

Reduced Risk of Hypoglycemia with Insulin Degludec Versus Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: A Meta-Analysis of 5 Randomized Begin Trials

(2013) Helena Rodbard et al.   Endocrine Practice

Type 1 diabetes

(2013) Mark A Atkinson et al.   LANCET

Insulin Detemir

(2012) Gillian M. Keating   DRUGS

Clinical Experience with Insulin Glargine in Type 1 Diabetes

(2010) Satish Garg et al.   Diabetes Technology & Therapeutics

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

(2010) Athena Philis-Tsimikas   Patient Preference and Adherence

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

(2008) M. Monami et al.   DIABETES OBESITY & METABOLISM